As of October 2026 — Disclosed Capitol has tracked 136 disclosed congressional trades in Vertex Pharmaceuticals Incorporated (VRTX) — 73:56 sell-heavy ratio — led by Ro Khanna (D).

Which members of Congress trade Vertex Pharmaceuticals Incorporated?

• Ro Khanna (D) — 63 disclosed trades in VRTX
• Michael McCaul (R) — 12 disclosed trades in VRTX
• David J. Taylor (R) — 3 disclosed trades in VRTX
• Lisa McClain (R) — 3 disclosed trades in VRTX
• Jefferson Shreve (R) — 3 disclosed trades in VRTX

Recent VRTX congressional trades

Buy vs. sell ratio & volume

Across the 136 disclosed congressional trades in Vertex Pharmaceuticals Incorporated (VRTX), members of Congress have reported 56 buys and 73 sells. The average 30-day alpha vs. the S&P 500 is -1.56%.

Does Vertex Pharmaceuticals Incorporated receive U.S. government contracts?

As of October 2025, Vertex Pharmaceuticals Incorporated has 88 federal contract award records on file from USAspending.gov — most recently -$69K from the Department of Defense on 2025-10-16.

Negative amounts are contract de-obligations. Browse and filter every award on the government contracts page.

Vertex Pharmaceuticals Incorporated financial snapshot (FY2025)

For fiscal year 2025, Vertex Pharmaceuticals Incorporated reported revenue of $12.00B and net income of $3.95B, per SEC filings.

Revenue

$12.00B

Operating income

$4.17B

Net income

$3.95B

Diluted EPS

$15.32

Net margin

32.9%

Free cash flow

$3.19B

Most recent reported quarter: Q2 FY2026 — revenue $3.33B, net income $1.10B.

Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.